

Cardiology-related adverse events of targeted therapies for CLL/SLL and MCL

References

1. Burger JA. Bruton Tyrosine Kinase Inhibitors: Present and Future. *Cancer J.* 2019;25(6):386-393.
2. Brown JR, Moslehi J, O'Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. *Haematologica.* 2017;102(10):1796-1805.
3. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as Initial Therapy for Patients With Chronic Lymphocytic Leukemia. *N Engl J Med.* 2015;373(25):2425-2427.
4. Sharman JP, Egyed M, Jurczak W, et al. Acabrutinib With or Without Obinutuzumab Versus Chlorambucil and Obinutuzumab for Treatment-Naive Chronic Lymphocytic Leukaemia (ELEVATE TN): A Randomised, Controlled, Phase 3 Trial. *Lancet.* 2020;395(10232):1278-1291.
5. Dickerson T, Wiczar T, Waller A, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. *Blood.* 2019;132(22):1919-1928.
6. Winqvist M, Andersson P-O, Asklid A, et al. Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort. *Haematologica.* 2019;104(5):e208-e201.
7. Ghia P, Pluta A, Wach M, et al. SCEND: Phase III, Randomized Trial of Acabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. *J Clin Oncol.* 2020;38(25):2849-2861.
8. Byrd JC, Woyach JA, Furman RR, et al. Acabrutinib in treatment-naive chronic lymphocytic leukemia. *Blood.* 2021;137(24):3327-3338.
9. Byrd JC, Hillmen P, Ghia P, et al. Acabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. *J Clin Oncol.* 2021;39(31):3441-3452.
10. Yazdy, MS, Mato, AR, Roeker, LE, et al. Toxicities and outcomes of acabrutinib-treated patients with chronic lymphocytic leukemia: A retrospective analysis of real world patients. *Blood.* 2019;134(Suppl 1):4311.
11. Tam CS, Robak T, Ghia P, et al. Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion. *Haematologica.* 2020;106(9):2354-2363.
12. Hillmen P, Brown JR, Eichhorst BF, et al. ALPINE: Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. *Future Oncol.* 2020;16(10):517-523.
13. Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. *Hypertension.* 2020;75(6):1334-1357.